Target intelligence / Profile preview

T cell receptor alpha joining 52 (TRAJ52)

Target
TRAJ52
Molecular classification
Other (Immunoglobulin gene segment)
01

Overview

T cell receptor alpha joining 52 (TRAJ52) is a genomic DNA segment that encodes one of the joining (J) elements used during the somatic recombination of T cell receptor (TCR) alpha chains in developing T lymphocytes[1][4][7][2]. It is not a protein target in the usual therapeutic sense, nor is it expressed independently; instead, it serves as one of the modular gene segments (joined with V and C regions) to generate the immense diversity of antigen-specific alpha chains comprising mature TCRs on T cell surfaces[1][2][6]. TRAJ52 itself is not directly targeted by drugs, is not a traditional receptor or enzyme, and does not act as a standalone molecule. Rather, its sequence contributes to the overall diversity of TCRs, which are essential for immune recognition. TRAJ52 is not considered a therapeutic target; its clinical or functional relevance comes only from its participation in the broader process of TCR assembly and the adaptive immune response[1][6][7].

Other names
TRAJ52T cell receptor alpha joining segment 52TCR alpha J52
02

Biological functions

T cell receptor diversity generationV(D)J recombinationAntigen recognition (indirectly, as part of assembled TCR)
03

Disease associations

Other (Indirect, as a genetic element involved in T cell function. Not directly implicated in disease.)

Beyond the preview

Go deeper on T cell receptor alpha joining 52 (TRAJ52).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 52 (TRAJ52).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call